Fenebrutinib significantly reduced the annualized relapse rate in patients with relapsing multiple sclerosis compared with teriflunomide.

A second clinical trial testing fenebrutinib for MS has met its main goal, once again beating approved Aubagio in reducing ...

Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...

PRINCETON, NJ, September 26, 2025 (EZ Newswire) -- Opioid addiction, including dependence on substances such as fentanyl and heroin, is widely acknowledged as a global public health and social safety ...

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel ...

The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically ...

Explainable Machine Learning to Predict Treatment Response in Advanced Non–Small Cell Lung Cancer To reduce costs in genomic studies of time-to-event phenotypes like survival, researchers often ...

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer After block 1 reinduction, patients age ...

Adding belzutifan to pembrolizumab after kidney cancer surgery cuts recurrence risk by 28%, helping high-risk patients stay ...